Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The trial will be conducted across eight sites in Maharashtra
The company has to approach the DCGI for approval to commence the trials
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Subscribe To Our Newsletter & Stay Updated
